| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.
|
Cell Cycle
|
2009
|
4.69
|
|
2
|
Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells.
|
Cell Cycle
|
2010
|
3.15
|
|
3
|
Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism.
|
Cell Cycle
|
2010
|
3.00
|
|
4
|
Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis.
|
Cell Cycle
|
2011
|
2.92
|
|
5
|
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment.
|
Cell Cycle
|
2010
|
2.80
|
|
6
|
Cytokine production and inflammation drive autophagy in the tumor microenvironment: role of stromal caveolin-1 as a key regulator.
|
Cell Cycle
|
2011
|
2.68
|
|
7
|
Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.
|
Cell Cycle
|
2012
|
2.55
|
|
8
|
Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors.
|
Cell Cycle
|
2010
|
2.32
|
|
9
|
The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism.
|
Cell Cycle
|
2010
|
2.26
|
|
10
|
The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.
|
Cell Cycle
|
2010
|
2.10
|
|
11
|
The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.
|
Cell Cycle
|
2010
|
2.07
|
|
12
|
Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis.
|
Antioxid Redox Signal
|
2011
|
2.04
|
|
13
|
Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment.
|
Cancer Biol Ther
|
2010
|
1.96
|
|
14
|
HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis.
|
Cell Cycle
|
2010
|
1.89
|
|
15
|
Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.
|
Am J Pathol
|
2009
|
1.87
|
|
16
|
Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling.
|
Cell Cycle
|
2010
|
1.74
|
|
17
|
Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production.
|
Cell Cycle
|
2012
|
1.63
|
|
18
|
Structural abnormalities of the cornea and lid resulting from collagen V mutations.
|
Invest Ophthalmol Vis Sci
|
2006
|
1.53
|
|
19
|
Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis.
|
Cell Cycle
|
2011
|
1.52
|
|
20
|
Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts.
|
Cancer Biol Ther
|
2011
|
1.48
|
|
21
|
Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.
|
Am J Pathol
|
2012
|
1.45
|
|
22
|
Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes.
|
J Cell Sci
|
2007
|
1.39
|
|
23
|
CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth.
|
Cell Cycle
|
2012
|
1.37
|
|
24
|
Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs "fertilizer".
|
Cell Cycle
|
2011
|
1.36
|
|
25
|
Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells.
|
Cell Cycle
|
2012
|
1.33
|
|
26
|
CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.
|
Cell Cycle
|
2012
|
1.29
|
|
27
|
Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production.
|
Cell Cycle
|
2012
|
1.29
|
|
28
|
Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection.
|
Cell Cycle
|
2011
|
1.29
|
|
29
|
Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells.
|
Cell Cycle
|
2012
|
1.25
|
|
30
|
Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine.
|
Cell Cycle
|
2011
|
1.24
|
|
31
|
Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue.
|
Cell Cycle
|
2012
|
1.23
|
|
32
|
Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism.
|
Cell Cycle
|
2012
|
1.22
|
|
33
|
Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth.
|
Oncotarget
|
2012
|
1.20
|
|
34
|
Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance.
|
Cell Cycle
|
2012
|
1.19
|
|
35
|
PPARgamma activation induces autophagy in breast cancer cells.
|
Int J Biochem Cell Biol
|
2009
|
1.14
|
|
36
|
Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
|
Cell Cycle
|
2013
|
1.14
|
|
37
|
Ketone body utilization drives tumor growth and metastasis.
|
Cell Cycle
|
2012
|
1.13
|
|
38
|
Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells.
|
Cell Cycle
|
2012
|
1.13
|
|
39
|
CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway.
|
Cancer Res
|
2010
|
1.07
|
|
40
|
Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells.
|
Cell Cycle
|
2012
|
1.05
|
|
41
|
Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth.
|
Cancer Biol Ther
|
2011
|
1.05
|
|
42
|
BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
|
Cell Cycle
|
2012
|
1.00
|
|
43
|
Left ventricular dysfunction in murine models of heart failure and in failing human heart is associated with a selective decrease in the expression of caveolin-3.
|
J Card Fail
|
2010
|
0.96
|
|
44
|
Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.
|
Cell Cycle
|
2012
|
0.95
|
|
45
|
Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation.
|
Am J Pathol
|
2009
|
0.91
|
|
46
|
Reverse Warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome?
|
Semin Oncol
|
2013
|
0.90
|
|
47
|
Metabolic remodeling of the tumor microenvironment: migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth.
|
Cell Cycle
|
2012
|
0.90
|
|
48
|
Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment.
|
Cell Cycle
|
2013
|
0.87
|
|
49
|
Cytokeratin15-positive basal epithelial cells targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype.
|
J Invest Dermatol
|
2006
|
0.86
|
|
50
|
Genetic ablation of Cav1 differentially affects melanoma tumor growth and metastasis in mice: role of Cav1 in Shh heterotypic signaling and transendothelial migration.
|
Cancer Res
|
2012
|
0.83
|
|
51
|
Compartment-specific activation of PPARγ governs breast cancer tumor growth, via metabolic reprogramming and symbiosis.
|
Cell Cycle
|
2013
|
0.82
|
|
52
|
Creating a tumor-resistant microenvironment: cell-mediated delivery of TNFα completely prevents breast cancer tumor formation in vivo.
|
Cell Cycle
|
2012
|
0.81
|
|
53
|
The milk protein α-casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis.
|
Cell Cycle
|
2012
|
0.81
|
|
54
|
Novel expression of vascular cell adhesion molecule-1 (CD106) by squamous epithelium in experimental acute graft-versus-host disease.
|
Am J Pathol
|
2002
|
0.81
|
|
55
|
Alterations in membrane caveolae and BKCa channel activity in skin fibroblasts in Smith-Lemli-Opitz syndrome.
|
Mol Genet Metab
|
2011
|
0.80
|
|
56
|
A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
|
Biol Blood Marrow Transplant
|
2004
|
0.76
|
|
57
|
12E2: a cloned murine dermal cell with features of dermal dendrocytes and capacity to produce pathologic changes resembling early Kaposi's sarcoma.
|
Am J Pathol
|
2003
|
0.75
|